» Authors » Meiling Lu

Meiling Lu

Explore the profile of Meiling Lu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 120
Citations 2038
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Li Z, Yan P, Hua C, Kong J, Wu W, et al.
Science . 2024 Dec; 387(6736):eadr0393. PMID: 39666823
Prokaryotes have evolved diverse defense strategies against viral infection, including foreign nucleic acid degradation by CRISPR-Cas systems and DNA and RNA synthesis inhibition through nucleotide pool depletion. Here, we report...
2.
Mu H, Hou X, Wu Z, Li J, Wang W, Lu M, et al.
Environ Health (Wash) . 2024 Oct; 2(10):702-711. PMID: 39474433
Environmental pollution from synthetic chemical mixtures has significant adverse impacts on marine ecosystems. However, identifying the main constituents of chemical mixtures that pose ecological threats is challenging due to the...
3.
Huang P, Yan P, Guo L, Fei W, Li Z, Liu J, et al.
Cell Res . 2024 Oct; 34(12):873-876. PMID: 39448873
No abstract available.
4.
Wang P, Lu M, Huang Y, Sun L, Han Z
J Thorac Dis . 2024 Aug; 16(7):4174-4185. PMID: 39144295
Background: Extracorporeal circulation auxiliary to open cardiac surgery (ECAOCS) is one of the most complex surgical procedures and carries a very high risk of death. We developed a nomogram from...
5.
Hu T, Ji Q, Ke X, Zhou H, Zhang S, Ma S, et al.
Commun Biol . 2024 Jul; 7(1):858. PMID: 39003402
R-loop-triggered collateral single-stranded DNA (ssDNA) nuclease activity within Class 1 Type I CRISPR-Cas systems holds immense potential for nucleic acid detection. However, the hyperactive ssDNase activity of Cas3 introduces unwanted...
6.
Lu M, Yu C, Zhang Y, Ju W, Ye Z, Hua C, et al.
Nat Commun . 2024 May; 15(1):4126. PMID: 38750051
Type I CRISPR-Cas systems employ multi-subunit effector Cascade and helicase-nuclease Cas3 to target and degrade foreign nucleic acids, representing the most abundant RNA-guided adaptive immune systems in prokaryotes. Their ability...
7.
Chen J, Xu X, Shao Y, Bian X, Li R, Zhang Y, et al.
Int J Biochem Cell Biol . 2024 Jan; 169:106539. PMID: 38290690
Doxorubicin (DOX), a widely used chemotherapy agent in cancer treatment, encounters limitations in clinical efficacy due to associated cardiotoxicity. This study aims to explore the role of AKT serine/threonine kinase...
8.
Wang Y, Dong S, Hu K, Xu L, Feng Q, Li B, et al.
J Transl Med . 2023 Nov; 21(1):858. PMID: 38012658
Background: Multiple myeloma (MM), an incurable disease owing to drug resistance, requires safe and effective therapies. Norcantharidin (NCTD), an active ingredient in traditional Chinese medicines, possesses activity against different cancers....
9.
Luo F, Lu M, Zhao L, Zhou P
Medicine (Baltimore) . 2023 Nov; 102(44):e34962. PMID: 37932997
Rationale: Branchiooculofacial syndrome (BOFS) is a rare autosomal dominant disorder with a diverse clinical phenotype. To summarise the clinical characteristics and genetic variations of neonatal-onset BOFS through a case study...
10.
Guo L, Huang P, Li Z, Shin Y, Yan P, Lu M, et al.
Nat Chem Biol . 2023 Nov; 20(4):512-520. PMID: 37932527
Short prokaryotic Ago accounts for most prokaryotic Argonaute proteins (pAgos) and is involved in defending bacteria against invading nucleic acids. Short pAgo associated with TIR-APAZ (SPARTA) has been shown to...